Alpine BioVentures, a Seattle-based venture capital firm committed to investing in and building innovative healthcare companies, added Jay Venkatesan, M.D., as a managing partner.
Dr. Venkatesan will lead the creation of new companies, identify investment opportunities and collaborate with innovators to develop new therapies that can impact patients’ lives.
Prior to joining Alpine, he was the executive vice president and general manager of Oncothyreon, Inc., which he joined after it was acquired by Alpine Biosciences, where he served as co-founder and CEO. Previously, Dr. Venkatesan was the founder, portfolio manager and managing director of Ayer Capital Management, a global healthcare long-short equity fund. Prior to that, he served as a director at Brookside Capital Partners, the hedge fund group affiliated with Bain Capital, where he co-managed healthcare investments and evaluated public and private investments in all healthcare subsectors. Earlier in his career, Dr. Venkatesan was involved in healthcare venture investing at Patricof & Co. Ventures (now Apax Partners) and consulting at McKinsey & Company.
In addition, he currently serves on the Board of Directors of Lion Biotechnologies and AuraSense Therapeutics.
Led by Mitchell H. Gold, M.D., founder and managing partner, Alpine is committed to investing in and building healthcare companies. The company’s portfolio includes Alpine Immune Sciences and Alpine Biosciences, which was acquired by Oncothyreon in 2014.